Date: 2016-05-18
Type of information: Granting of a patent
Product name: ZW25 - anti-HER2 bispecific antibody
Compound: anti-HER2 bispecific antibody
Therapeutic area: Cancer - Oncology - Rare diseases
Action mechanism: bispecific antibody. This bispecific antibody targets two different epitopes of the human epidermal growth factor receptor 2 (HER2) protein, which is over-expressed on the surface of many tumor types, including a subset of breast, gastric, lung, and ovarian cancers.
Company: Zymeworks (Canada)
Disease: ovarian cancer
Latest news: * On May 18, 2016, the FDA has granted orphan drug designation for anti-HER2 bispecific antibody ZW25 for treatment of ovarian cancer. ZW25 is currently in development in preparation for an IND filing in early 2017.
Patents:
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE: OTC status: Other news:
